Clinical trials: HCV
Hepatitis C, Heart Transplant
Expanding the Pool in Orthotopic Heart Transplantation
This is an open-label, pilot trial to test the safety and efficacy of transplantation of hearts from HCV seropositive non-viremic (HCV Ab+/NAT-) and HCV seropositive viremic (HCV Ab+/NAT+) donors to HCV seronegative recipients on…
- Conditions
- Hepatitis C, Heart Transplant, Cardiac Transplant
- Trial name
- NCT03222531
- Testing
- sofosbuvir/velpatasvir
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mary E. Keebler, MD
Hepatitis C, Chronic
ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632)
This is a Phase 4, retrospective and observational, multicenter, national (Brazil), open, noncomparative, and nonrandomized study, which does not have visits. This study will be conducted in accordance to Good Clinical Practices.
- Trial name
- ATHENAS (NCT00856024)
- Testing
- Peginterferon alfa-2b, Ribavirin
- Volunteers
- 902 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C Infection
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination.
- Trial name
- NCT02429583
- Testing
- Recombivax
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Rockefeller University
Hepatocellular Carcinoma, Hepatitis C, Chronic
Primary Prevention Hepatocellular Carcinoma by Metformin
Metformin treatment during 36 months could be associated with decreased risk of HCC occurrence and liver related death in patients with compensated HCV cirrhosis and insulinoresistance.
- Conditions
- Hepatocellular Carcinoma, Hepatitis C, Chronic, Cirrhosis
- Trial name
- METFOVIR (NCT02319200)
- Testing
- Metformin
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Hepatitis C Virus Genotype 1
A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Based on 12-week on-treatment data, at least 1 dose of BMS-824393 can be identified which is safe, well tolerated, and has sufficient antiviral activity to progress to late stage clinical trials when combined with pegIFNα/RBV for…
- Trial name
- NCT01142700
- Testing
- BMS-824393, Peginterferon Alpha-2a, Ribavirin
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)
This is a controlled, randomized, parallel-groups, open-label, multinational study designed to evaluate the efficacy and safety of PEG-Intron® (pegylated interferon alfa-2b) plus Rebetol® (ribavirin) in subjects with chronic…
- Trial name
- NCT00265395
- Testing
- Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®), Combination of pegylated interferon alfa-2b and ribavirin
- Volunteers
- 1,428 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis, Hepatitis C
An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients
The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1…
- Conditions
- Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
- Trial name
- NCT02103439
- Testing
- Algeron, PegIntron
- Where
- 6 sites in Russia
- Volunteers
- 140 people
- Sponsor
- Biocad
Hepatitis C, Chronic
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus…
- Trial name
- NCT00394277
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 184 sites in United States, Belgium and 13 more
- Volunteers
- 1,175 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV).
- Trial name
- NCT00962936
- Testing
- CT-011
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- CureTech Ltd
Hepatitis C
Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs
Neuropsychiatric adverse effects of direct acting antiviral drugs, especially Sofosbuvir and Daclatasvir combination therapy (with or without ribavirin) in patients with chronic hepatitis C , genotype four (the predominant…
- Trial name
- NCT03268317
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatitis C Virus Genotype 4 Infection
Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen
ANRS HC 33 is a pilot study to assess efficacy and safety of a DCV 3DAA therapy with Asunaprevir, Daclatasvir and BMS-791325 in HCV genotype 4-infected patients after failure of pegylated Interferon-Ribavirin regimen.
- Trial name
- QUATTROTURBO (NCT02309450)
- Testing
- .Asunaprevir, Daclatasvir and BMS - 791325
- Where
- France
- Sponsor
- ANRS, Emerging Infectious Diseases
Hepatitis C, Diagnostic Self Evaluation
HCV Self-testing in Pakistan
To achieve the goal of elimination of hepatitis C infection in Pakistan, the strategy of elimination needs to be increasingly directed towards case finding through mass screening in rural or peri-urban communities to identify and…
- Trial name
- NCT04971538
- Testing
- OraQuick® HCV Self-Test
- Where
- Pakistan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Hepatitis C
A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)
This study is being done to find out if participants with insulin resistance and hepatitis C virus genotype 1 (HCV GT1) infections who failed dual therapy with peginterferon alfa (PegIFN) + ribavirin (RBV) will benefit from the…
- Trial name
- NCT01770223
- Testing
- boceprevir, PegIFN-2b, RBV
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Hematologic Malignancy
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with hematological malignancy.
- Trial name
- NCT03903185
- Testing
- Ledipasvir / Sofosbuvir Oral Product
- Where
- 2 sites in Egypt
- Volunteers
- 24 people
- Sponsor
- Ain Shams University
Chronic Hepatitis C, Insulin Resistance
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the development of type 2 diabetes and HCV infection itself may promote insulin resistance, irrespective of the severity of liver disease.
- Trial name
- NCT00370617
- Testing
- metformin
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- University of Turin, Italy
Hepatitis C, Thalassemia
Pegasys® Plus Ribavirin in Thalassemic Patients With Hepatitis C Virus Infection
Antiviral treatment of HCV in thalassemia has raised concerns of ribavirin-induced hemolysis and increased iron loading. Blood Transfusion in Thalassemic patients are a known high risk for acquiring hepatitis C.
- Trial name
- NCT00707850
- Testing
- PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)
- Where
- Iran
- Volunteers
- 300 people
- Sponsor
- Baqiyatallah Medical Sciences University
Liver Cirrhosis
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
- Trial name
- OP-724-H202 (NCT07681089)
- Testing
- Foscenvivint
- Where
- 4 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Kiminori Kimura, MD
Hepatitis C Virus Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
This study is to evaluate the antiviral efficacy, safety, and tolerability of combination therapy with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) + vedroprevir (VDV) ± ribavirin (RBV) for 8 weeks in…
- Trial name
- NCT02226549
- Testing
- LDV/SOF, VDV, RBV
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic Pain
Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
The study is to investigate whether alisporivir (ALV; DEB025) alone or in combination with either ribavirin (RBV) or peginterferon alfa-2a (PEG) is more efficient compared to standard of care (PEG+RBV) in treatment-naïve…
- Trial name
- NCT01215643
- Testing
- Alisporivir, Peginterferon alfa-2a, Ribavirin
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 340 people
- Sponsor
- Debiopharm International SA
Hepatitis C, Hepatitis B
Insulin Resistance Associated With Chronic Hepatitis C (CHC) and the Effect of Antiviral Therapy
The literature suggests that there may be an association between hepatitis C and type 2 diabetes mellitus independent of the presence of cirrhosis, the likely mechanism for which is insulin resistance.
- Trial name
- NCT00188240
- Testing
- Pegasys; Copegus.
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- University Health Network, Toronto